New app helps diabetes patients stay on track with insulin

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have been diagnosed (clinically) with T1D for at least 1 year or are patients with T2D on basal bolus insulin therapy for at least 6 months * HbA1c ≥8% as confirmed by point-of-care test at screening * Are currently using the Dexcom G6 CGM or agree to start using the Dexcom G6 during the study and agree to switch to Glooko RMA * Are currently using Humalog ® insulin or another rapid acting insulin analogue (e.g., Apidra® , or Novorapid ® ) and agree to switch to study-provided Humalog mealtime insulin for duration of trial * Have been prescribed ≥3 doses of bolus insulin per day * Must be taking a stable insulin dose regimen (per investigator's judgement) for at least 3 months preceding study screening * Have in-home refrigeration for storage of insulin Exclusion Criteria: * Previously used the Glooko RMA and/or Dexcom G6 CGM and were judged by the investigator to be non-adherent * Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed * Have previously used or have been using an approved or investigational connected pen system within the 3 months prior to screening * Are currently breastfeeding, pregnant, or plan to become pregnant during the next 4-6 months * Are on ultra-rapid insulin (e.g., Fiasp or Lyumjev) or rapid acting human insulin (i.e., Humulin) for previous 3 months, at the time of screening * Are currently undergoing dialysis treatment or have any other medical condition which may preclude them from participating in this trial as per the investigator's judgement * Have vision loss or vision impairment that does not allow recognition of Glooko RMA screen features